A change from cytology to HPV testing in primary cervical cancer screening implicitly changes the requirements for quality control and quality assurance compared to the current cytology based screening.
For molecular HPV screening, quality control is not only required for the actual screening test, but will also be required for bio-banking of cervical screening samples with respect to audit and quality assurance of the overall screening program performance. Quality control requirements will -to a large degree- be defined by choice of sampling medium and by choice of HPV assay. But how to design quality control measures on molecular HPV cervical screening activities?
The presentation will focus on 1) the quality of liquid based cytology medias, ThinPrep and SurePath, for use with molecular HPV assays, 2) tools to quality control HPV based screening in individual laboratories and in series of laboratories, 3) describing the impact of assay specific cross reactivity to non-targeted HPV genotypes, and the challenges with respect to false-positive screening results when using HPV assays with bulk detection of many genotypes. Finally, the presentation will take a look at the biobanking requirements for longitudinal quality control and assurance for audit purposes. The latter is expected to be a large and different work task compared to storing cytology slides for quality assurance.
N/A
N/A
N/A
Laboratory audit as part of the quality assessment of a primary HPV-screening program. Hortlund M et al. J Clin Virol. 2016
Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
Preisler S et al. BMC Cancer. 2016
Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.
Engesæter B et al. BMC Infect Dis. 2016